- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02423577
Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain
A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects Who Are Experimentally Infected With a Challenge Strain of Influenza A Virus
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- Quintiles Drug Research Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male and non-pregnant, non-lactating female subjects of 18 to 50 years of age inclusive
- Body Mass Index (BMI) of 18 to 32 kg/m2 inclusive and body weight of 50 to 110 kg inclusive.
- Normal spirometry values at Screening and Baseline
- Post-menopausal women with amenorrhea for at least 2 years will be eligible
- Females of childbearing potential must use two acceptable birth control methods throughout the study and for 30 days after the last dose of the IMP:
Male subjects:
- Must agree to use a condom (or diaphragm) plus spermicide in female partner) from the time of the first dose of IMP through 90 days after the last dose.
- Must agree to not donate sperm for 90 days after the last dose of IMP.
- Documented evidence of vasectomies in males for 180 days minimum prior to the first dose of the IMP is an acceptable form of contraception.
- Males who claim abstinence as their method of contraception are allowed provided they agree to use a double barrier method (diaphragm plus spermicide in female partner or condom) should they become sexually active from screening to 90 days after the last dose of IMP.
- Willing and able to provide written informed consent.
- Willing and able to adhere to the lifestyle guideline restrictions outlined in the protocol
Exclusion Criteria:
Subjects may not be enrolled in the study if any of the following exclusion criteria are fulfilled:
- Evidence of or history of clinically significant oncologic, pulmonary, hepatic, gastrointestinal, cardiovascular, hematologic, metabolic, neurological, immunologic, nephrologic, endocrine , or psychiatric disease.
- Current infection of any nature unless agreed as insignificant to the study by the Investigator and Medical Monitor.
- Nasal abnormalities, including nasal septum deviation, septum perforations, or polyps; history of recurrent epistaxis; history of sinus surgery and/or persistent hypertrophic inferior turbinates.
- Significant abnormalities at screening in safety laboratory tests, ECGs, or spirometry.
- Broncho-reactive airway disease (asthma, chronic obstructive pulmonary disease, current allergic rhinitis, cystic fibrosis, chronic bronchitis, emphysema). Individuals with a history of childhood asthma are not necessarily excluded and acceptable for screening.
- History of significant nasal irritation from use of nasal sprays or drops.
- History of drug or alcohol abuse within the past 2 years
- Nicotine product users
- Received an investigational drug or participated in another research study within 90 days of the first dose of IMP.
- Participated in a previous investigational study of FF-3.
- History of influenza vaccination with a live or attenuated vaccine within the previous year
- Use of prescription drugs within 14 days prior to the first dose of IMP, excepting oral contraceptives.
- Received any non-prescription medications, vitamins, or dietary supplements within 14 days of administration of the first dose of IMP, unless both the Principal Investigator and the Medical Monitor grant prior approval. Herbal supplements must be discontinued 7 days prior to the first dose of IMP.
15. Tested positive for alcohol at screening or admission to the CRU. 16. Positive urine pregnancy test at the Screening Visit or positive serum pregnancy test on admission to the CRU (females only).
17. Positive test for HIV, hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (anti-HCV) at the screening visit.
18. Positive urine drug test at the screening visit or at admission to the CRU. 19. Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.
20. Subjects who have donated blood or experienced other significant blood loss within 56 days of screening for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo dry powder administered by nasal inhalation
|
Experimental: FF-3 dry powder
FF-3
|
FF-3 dry powder administered by nasal inhalation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequencies of Viral Shedding
Time Frame: Day 2 to Day 10
|
Percentage of Subjects Demonstrating Viral Shedding.
|
Day 2 to Day 10
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AIT02-2001
- 2015-001103-31 (EudraCT Number)
- HHSN272201400003C (Other Grant/Funding Number: National Institute of Health, NIAID)
- DMID 14-0052 (Other Identifier: Division of Microbiology and Infectious Diseases)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on FF-3 dry powder
-
AlgiPharma ASImperial College London; Cystic Fibrosis Foundation; University Hospital of Cologne and other collaboratorsWithdrawnCystic FibrosisGermany
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
-
Esfam Biotech Pty LtdNot yet recruiting
-
Orion Corporation, Orion PharmaCompletedPulmonary Disease, Chronic Obstructive | AsthmaUnited Kingdom, Finland
-
Vectura LimitedUCB PharmaCompleted
-
GB002, Inc.Not yet recruitingPulmonary Arterial HypertensionUnited States
-
GB002, Inc.RecruitingPulmonary Arterial HypertensionUnited States, Spain, Israel, Korea, Republic of, Netherlands, France, Singapore, United Kingdom, Lithuania, Australia, Latvia, Argentina, Portugal, Greece, Czechia, Puerto Rico, Belgium, Italy, Poland, Romania, Serbia, Austria, Chile, Denma... and more
-
GB002, Inc., a wholly owned subsidiary of Gossamer...RecruitingPulmonary Arterial HypertensionUnited States, Australia, Spain, Czechia, France, Germany, United Kingdom, Belgium
-
GB002, Inc., a wholly owned subsidiary of Gossamer...CompletedPulmonary Arterial HypertensionUnited States, United Kingdom